Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Ramaekers, BLT; Wolff, RF; Pouwels, X; Oosterhoff, M; Van Giessen, A; Worthy, G; Noake, C; Armstrong, N; Kleijnen, J; Joore, MA

Ramaekers, BLT (reprint author), Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment KEMT, POB 5800, NL-6202 AZ Maastricht, Netherlands.

PHARMACOECONOMICS, 2018; 36 (8): 917

Abstract

The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz (R)), t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索